Overview

Sexual Dysfunction in Gynecologic Oncology Patients

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This project will evaluate sexual dysfunction in women who have had surgery for gynecologic cancer. The subjects will complete a set of questionnaires about health, daily living, sexual encounters, and pain before their surgery and three times following. Each subject will be randomized to receive either lidocaine or a placebo that is applied vaginally immediately prior to any sexual encounters for approximately 6 months while maintaining a journal of sexual encounters and pain. The subjects and healthcare providers will be blinded to the treatment randomization until intervention and data collection is complete. Total participation will last up to one year from the date of enrollment. Subjects will visit the clinic at the same time as regular cancer care visits, receive the blinded intervention and complete the surveys.
Phase:
Phase 4
Details
Lead Sponsor:
David Bender
Treatments:
Lidocaine